Results 21 to 30 of about 4,636,683 (298)

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

open access: yesFrontiers in Oncology, 2021
The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis.
Dan Pu   +8 more
doaj   +1 more source

Immunotherapy of lung cancer: An update [PDF]

open access: yes, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A.   +15 more
core   +1 more source

MDT Treatment of Small Cell Lung Cancer Complicated with Adenocarcinoma: 
A Case Report and Literature Review

open access: yesChinese Journal of Lung Cancer, 2021
Small cell lung cancer (SCLC) is the most malignant lung cancer with the highest mortality. At present, the first-line standard treatment is still based on Etoposide and Platinum chemotherapy.
Zihan QU   +5 more
doaj   +1 more source

Chronic obstructive pulmonary disease: a complex comorbidity of lung cancer [PDF]

open access: yes, 2011
Chronic obstructive pulmonary disease (COPD) is a major burden throughout the world. It is associated with a significantly increased incidence of lung cancer and may influence treatment options and outcome.
Derek Grose MRCP, FRCR   +3 more
core   +1 more source

Lung Cancer in Pulmonary Fibrosis: Tales of Epithelial Cell Plasticity [PDF]

open access: yes, 2011
Lung epithelial cells exhibit a high degree of plasticity. Alterations to lung epithelial cell function are critically involved in several chronic lung diseases such as pulmonary fibrosis.
Königshoff, M.   +2 more
core   +1 more source

EGFR-TKI ADR Management Chinese Expert Consensus

open access: yesChinese Journal of Lung Cancer, 2019
ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China.
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
doaj   +1 more source

Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors

open access: yesChinese Journal of Lung Cancer, 2020
Epigenetic modification is closely related to the occurrence and development of tumors. It mainly regulates gene function and expression level through DNA methylation, histone modification, regulation of non-coding RNA and chromatin structure ...
Pan WANG   +10 more
doaj   +1 more source

Lung cancer epidemiology in North Sardinia, Italy [PDF]

open access: yes, 2013
Background The aim of this study was to analyze and describe the epidemiological characteristics and trends of lung cancer in North Sardinia, Italy, in the period 1992–2010.
Attene, Federico   +15 more
core   +1 more source

Exploring the incidence of lung cancer in small areas across Scotland [PDF]

open access: yes, 2015
Lung cancer is one of the most important causes of 'avoidable deaths' globally and is responsible for approximately 900,000 deaths per year. However, lung cancer rates tend to be higher for males than for females and the disease also varies ...
Pearce, James R,
core   +2 more sources

Symptom trajectories during chemotherapy in patients with non‐small cell lung cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting enhanced recovery after chemotherapy

open access: yesThoracic Cancer, 2021
Background Lung cancer, mainly non‐small cell lung cancer (NSCLC), is one of the leading causes of death worldwide. Currently, chemotherapy is still the most significant treatment strategy for NSCLC.
Jinghao Liu   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy